Organ damage is a common complication in the process of HSCT. Among targeted organ, the incidence of acute kidney injury is high, ranging from 26.4 to 62.2% [1] [2] [3] [4] [5] [6] [7] during HLA-identical matched HSCT. Despite the overall improvement in outcomes after hematopoietic-cell transplantation, acute kidney injury remains a frequent complication and contributes to the morbidity and mortality [1, 2, 4, 8] . In the recent decades, haplo-HSCT developed rapidly and could achieve outcomes similar to those of matched-sibling donor (MSD) HSCT for many diseases such as intermediate and high risk acute myelogenous leukaemia, high-risk acute lymphoblastic leukaemia and so on [9, 10] . However, until to now, studies of AKI on the field of haplo-HSCT are lacking.
evaluated for renal function in the first 100 days, where 201 patients developed AKI and 152 cases were the control group. Baseline creatinine was evaluated 1 week before preconditioning, and renal function was re-evaluated after HSCT at least twice a week. According to serum creatinine concentration, AKI was classified as follows: grade 0, normal renal function; grade 1, renal dysfunction corresponded to a less than 1.5-fold rise in baseline serum creatinine; grade 2, renal dysfunction corresponded to greater than or equal to a twofold rise in baseline serum creatinine; grade 3, renal dysfunction corresponded to greater than or equal to a three fold rise in baseline serum creatinine. The urine output or glomerular filtrate rate (GFR) was not a basis for judging AKI. The predominant preconditioning regimen consisted of cytarabine (4 g/[m 2 day] on −10 to −9 days), busulfan (BU, 3.2 mg/[kg day] on −8 to −6 days), cyclophosphamide (CY, 1.8 g/[m 2 day] on −5 to −4 days), simustine (250 mg/m 2 on day −3), and rabbit antithymocyte globulin (ATG; thymoglobulin, 2.5 mg/kg, −5 to −2 days; Sanofi, France). Thirteen patients also received total body irradiation, as part of the conditioning regimen. Five patients received a preconditioning regimen consisting of cytarabine (4 g/[m 2 day] −10 to −9 days), busulfan (BU, 3.2 mg/[kg day] on −8 to −6 days), fludarabine (30-35 mg/[m 2 day] on −6 to −2 days), simustine (250 mg/m 2 on day −3), and rabbit ATG (2.5 mg/kg, −5 to −2 days). One patient received a preconditioning regimen that consisted of fludarabine, cyclophosphamide and rabbit ATG. One patient received reduced-intensity conditioning, which consisted of cytarabine (4 g/[m 2 day] −10 to −9 days), busulfan (BU, 3.2 mg/ [kg day] on −8 to −6 days), fludarabine (30 mg/[m 2 day] on −6 to −2 days), cyclophosphamide (CY 1.4 g/[m 2 day] on −5 to −4 days), and rabbit ATG (2.5 mg/kg on −5 to −2 days). GVHD prevention and treatment were as follows: all patients received cyclosporine A, mycophenolate mofetil, and short-term methotrexate for GVHD prophylaxis. The first-line treatment for acute GVHD treatment includes adjusting cyclosporine concentration to effective target and (1-99). There was no significant difference in terms of age, gender, basic creatinine level, underlying haematological disease, HLA matching degree, TBI applied in the preconditioning regimen, CD34 and MNC infusion quantity, CMV infection, haemorrhagic cystitis, and VOD between grade 2/3 AKI and grade 0/1 AKI. (Table 1 ). There were significant differences in whether using amphotericin B, sepsis, grade 3 or 4 GVHD, the highest total bilirubin, basic creatinine level and EBV infection in the univariate analysis. In the multivariate analysis, amphotericin B (OR = 4.946, 95%CI: 1.691-14.472, p = 0.004), sepsis (OR = 3.008, 95%CI: 1.427-6.340, p = 0.004), greater than grade 2 GVHD (OR = 3.395, 95%CI: 1.757-6.558, p < 0.001), and Epstein-Barr virus (EBV) infection (OR = 2.089, 95% CI: 1.047-4.168, p = 0.037) were independent risk factors for grades 2 or 3 AKI occurrence (Table 1) . A total of 94 patients died during the follow-up period. 29 relapsed patients died from recurrent disease, 17 patients died from GVHD and direct causes of 31 patients were infection. Other death causes include thrombotic microangiopathy (TMA), diffuse alveolar haemorrhage (DAH) and so on (see supplement materials). AKI had no effect on disease relapse (p = 0.47). Univariate analysis for overall mortality was conducted for this study cohort, and significant factors included grade 2 and 3 AKI, sepsis, VOD, grade 3 and 4 GVHD, and EBV viremia. Multivariate regression analysis showed that grade 2 and 3 AKI (p = 0.001), sepsis (p = 0.045), VOD (p = 0.016), and grade 3 and 4 GVHD (p = 0.023) were independent risk factors for overall survival (see supplement materials).
AKI after HSCT impacts both OS and PFS. The overall 2-year OS was 72.8%; and estimated 2-year OS of the control group, grade 1-3 subgroup of AKI was 78.9%; and 75.8% (p = 0.41), 58.7% (p < 0.001), and 44.6% (p < 0.001), respectively. The estimated 2-year PFS was 68.1%. The 2-year PFS of the control group, grade 1-3 subgroup of AKI was 72.2%; and 75.9% (p = 0.91), 52.1% (p = 0.001), and 45.7% (p < 0.001), respectively (Fig. 1) .
To the best of our knowledge, this is the first largest retrospective single arm study to analyse the incidence, risk factor of AKI and impact on prognosis of haplo-HSCT. Our study is the first to identify the incidence of AKI undergoing haplo-allo HSCT was 44.0%. A great range in the incidence of AKI is reported literature; from 26.4 to 62.2% in cohorts of patients receiving autologous or allogeneic HSCT [1] [2] [3] [4] [5] [6] [7] . This considerable difference in incidence rates has been ascribed to subjects' preconditioning regimens, graft type, allotransplant or auto transplant, children or adult, etc. [8, [11] [12] [13] . Our study showed that the cumulative incidence of acute kidney injury in this cohort was 44%. Because of the great range in the literature, and since our study did not have the same period controls, whether HLA locus-matched has an effect on AKI occurrence remains unknown. Unlike previous studies, VOD was not proved to be a risk factor in our results. Although volume overload, oedema, portal hypertension and diuretics in the disease course of VOD all can cause low renal perfusion and renal tubular damage, and lead to AKI, the incidence of VOD in this cohort was quite low, and it may explain why VOD was not identified as a risk factor. Another one of our study's findings was that EBV infection, not CMV infection was correlated with AKI occurrence and actually we cannot give a definite reason. Similarly, as mentioned in previous studies, amphotericin B, sepsis, grade III-IV GVHD, and hyperbilirubinaemia were risk factors for AKI occurrence [9, 10, 14] , and these findings accord with our own result. As a definite nephrotoxic drug, amphotericin B can cause vasoconstriction, leading to renal cortical ischaemia and reduced glomerular filtration rate. Infection can cause haemodynamic abnormalities, and also lead to inflammation reaction, which can result in arterioles constriction and low renal perfusion. Multiple cytokine release in severe GVHD can lead to renal injury, and intestinal involvement due to GVHD, and also can decrease renal perfusion, along with hepatic GVHDrelated liver dysfunction and hepato-renal syndrome, which can contribute to AKI. The difference between auto and allo HSCT also supports GVHD as one of AKI's pathogenic factors. Hyperbilirubinaemia can be a result of hepatic GVHD or laboratory manifestation of thrombotic microangiopathy. Several studies showed that AKI, after sibling HLAmatched haematopoietic transplantation, was an independent risk factor for transplantation-related mortality, and this finding is in accordance with our results. More definitely, our results showed that grade 2 and 3 AKI would have an impact on PFS and OS and that the HR could be 2.185; the 2-year OS in the grade 2 and 3 AKI group was 58.7% (p < 0.001) and 47.1% (p < 0.001), respectively.
In conclusion, we demonstrate that AKI was a common complication of haplo-HSCT and that severe GVHD, sepsis, amphotericin B and EBV infection were risk factors for AKI occurrence. Grade 2 or more severe AKI was an independent risk factor for mortality. Future explorations of AKI complications after haplo-HSCT are of great importance, particularly prospective studies.
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